Comparative Pharmacology
Head-to-head clinical analysis: LANOPHYLLIN versus THEOLAIR SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANOPHYLLIN versus THEOLAIR SR.
LANOPHYLLIN vs THEOLAIR-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is 7-9 hours in healthy adults; increases to 20-30 hours in congestive heart failure, cirrhosis, or severe COPD; decreases to 3-5 hours in smokers (tobacco or marijuana) due to enzyme induction.
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; hepatic metabolism accounts for 90%, with metabolites excreted in urine. Biliary/fecal excretion is negligible (<2%).
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator